AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
dichlorophen 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 863 | 97-23-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Nontoxic laxative vermicide effective for taenia infestation. It tends to produce colic and nausea. It is also used as a veterinary fungicide, anthelmintic, and antiprotozoan. (From Merck, 11th ed.)
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 4.733 | Moderate | 0.65 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.446 | Moderate | 0.65 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 34.198 | 10^-6 cm/s | Moderate | 0.65 |
| dh-clint | Dog hepatocyte intrinsic clearance | 248.886 | uL/min/10^6 cells | Moderate | 0.65 |
| dppb | Dog plasma protein binding (% unbound) | 0.050 | % | Moderate | 0.65 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 0.270 | % | Moderate | 0.65 |
| herg | hERG pIC50 | 4.952 | pIC50 | Moderate | 0.65 |
| hh-clint | Human hepatocyte intrinsic clearance | 2223.310 | uL/min/10^6 cells | Moderate | 0.65 |
| hlm-clint | Human liver microsomal intrinsic clearance | 36.644 | uL/min/mg protein | Moderate | 0.65 |
| hppb | Human plasma protein binding (% unbound) | 0.210 | % | Moderate | 0.65 |
| kinase-safety-class | ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK14,MAPK7,MAPK8,MAPK9,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 | 59 | |||
| kinase-selectivity-class | AXL,EIF2AK3,GRK2,MAP2K6,MAPK8,TEK | 6 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.528 | Moderate | 0.65 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 500.035 | Moderate | 0.65 | |
| mppb | Mouse plasma protein binding (% unbound) | 0.140 | Moderate | 0.65 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.560 | Moderate | 0.65 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 0.280 | % | Moderate | 0.65 |
| rh-clint | Rat hepatocyte intrinsic clearance | 353.183 | uL/min/10^6 cells | Moderate | 0.65 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 5.110 | % | Moderate | 0.65 |
| rppb | Rat plasma protein binding (% unbound) | 0.120 | % | Moderate | 0.65 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 20.989 | uM | Moderate | 0.65 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | P02DX02 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTHELMINTICS ANTICESTODALS Other anticestodals |
| MeSH PA | D000871 | Anthelmintics |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000923 | Anticestodal Agents |
| MeSH PA | D000935 | Antifungal Agents |
| MeSH PA | D000977 | Antiparasitic Agents |
| MeSH PA | D000980 | Antiplatyhelmintic Agents |
| MeSH PA | D000981 | Antiprotozoal Agents |
| CHEBI has role | CHEBI:35443 | anthelminthic drug |
Related Drugs by ATC class:
P02DX Other anticestodals 1 drug
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Open-angle glaucoma | indication | 84494001 | DOID:1067 |
| Secondary glaucoma | indication | 95717004 | |
| Angle-closure glaucoma | indication | 392291006 | DOID:13550 |
| Malignant glaucoma | off-label use | 10100008 | |
| Renal tubular acidosis | contraindication | 1776003 | DOID:14219 |
| Respiratory acidosis | contraindication | 12326000 | |
| Hyperkalemia | contraindication | 14140009 | |
| Metabolic acidosis, normal anion gap, acidifying salts | contraindication | 18104000 | |
| Diabetes mellitus type 2 | contraindication | 44054006 | DOID:9352 |
| Diabetes mellitus type 1 | contraindication | 46635009 | DOID:9744 |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Decreased respiratory function | contraindication | 80954004 | |
| Hyponatremia | contraindication | 89627008 | |
| Gout | contraindication | 90560007 | DOID:13189 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Disease of blood AND/OR blood-forming organ | contraindication | 191124002 | DOID:74 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Disorder of electrolytes | contraindication | 237840007 | |
| Primary adrenocortical insufficiency | contraindication | 373662000 | |
| Recurrent Calcium Renal Calculi | contraindication |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cats | Removal of ascarids, Toxocara canis | Indication |
| Cats | Removal of hookworms, Ancylostoma caninum | Indication |
| Cats | Removal of tapeworms, Taenia pisiformis | Indication |
| Cats | Removal of tapeworms, Dipylidium caninum | Indication |
| Cats | Removal of tapeworms, Echinococcus granulosus | Indication |
| Cats | Removal of hookworms, Uncinaria stenocephala | Indication |
| Cats | Removal of ascarids, Toxascaris leonina | Indication |
| Dogs | Removal of ascarids, Toxocara canis | Indication |
| Dogs | Removal of hookworms, Ancylostoma caninum | Indication |
| Dogs | Removal of tapeworms, Taenia pisiformis | Indication |
| Dogs | Removal of tapeworms, Dipylidium caninum | Indication |
| Dogs | Removal of tapeworms, Echinococcus granulosus | Indication |
| Dogs | Removal of hookworms, Uncinaria stenocephala | Indication |
| Dogs | Removal of ascarids, Toxascaris leonina | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Vermiplex | Intervet Inc. | 2 |
| Happy Jack Tapeworm Tablets | Happy Jack Inc. | 1 |
| Anaplex Caps, Canine and Feline Wormer Caps | Cronus Pharma Specialities India Private Limited | 2 |
| Difolin No. 1 Capsules, Difolin No. 2.5 Capsules, Difolin No. 25 Capsules, Difolin No. 40 Capsules, Difolin No. 5 Capsules | Zoetis Inc. | 2 |
| Tri-Plex Worm Capsules | Intervet Inc. | 2 |
| Trivermicide Worm Capsules | Happy Jack Inc. | 2 |
| Worm Capsules | Farnam Companies Inc. | 2 |
| D & T Worm Capsules | Cronus Pharma Specialities India Private Limited | 2 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.56 | acidic |
| pKa2 | 11.34 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Indoleamine 2,3-dioxygenase 1 | Enzyme | IC50 | 4.15 | CHEMBL | |||||
| Solute carrier family 22 member 1 | Transporter | IC50 | 5.08 | CHEMBL | |||||
| 78 kDa glucose-regulated protein | Cytosolic other | IC50 | 4 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| N0000166606 | NUI |
| 3351 | RXNORM |
| C0012082 | UMLSCUI |
| CHEBI:34689 | CHEBI |
| JAL | PDB_CHEM_ID |
| CHEMBL33845 | ChEMBL_ID |
| DB11396 | DRUGBANK_ID |
| D004003 | MESH_DESCRIPTOR_UI |
| 3037 | PUBCHEM_CID |
| 674 | INN_ID |
| T1J0JOU64O | UNII |
| 004478 | NDDF |
| 255999002 | SNOMEDCT_US |
| 411343001 | SNOMEDCT_US |
| T1J0JOU64O | INXIGHT DRUGS |
Pharmaceutical products:
None